Dr. Cortes on BP-100.01 in Patients With Relapsed/Refractory AML

Jorge E. Cortes, MD
Published: Friday, Apr 01, 2016



Jorge E. Cortes, MD, deputy department chair, professor of Medicine and Internist, chair, AML Sections, D. B. Lane Cancer Research Distinguished Professor for Leukemia Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action for BP-100.01.

BP-100.01 is an oligonucleotide liposome-incorporated antisense that is targeted against growth receptor bound protein-2 (GRB-2), Cortes explains. GRB-2 is a component that transmits the signal of certain kinases such as BCR-ABL to downstream receptors, such as MEK. By blocking this signal, delivery will be prevented.

This agent could be beneficial in patients with both acute myeloid leukemia and chronic myeloid leukemia, Cortes adds.



Jorge E. Cortes, MD, deputy department chair, professor of Medicine and Internist, chair, AML Sections, D. B. Lane Cancer Research Distinguished Professor for Leukemia Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action for BP-100.01.

BP-100.01 is an oligonucleotide liposome-incorporated antisense that is targeted against growth receptor bound protein-2 (GRB-2), Cortes explains. GRB-2 is a component that transmits the signal of certain kinases such as BCR-ABL to downstream receptors, such as MEK. By blocking this signal, delivery will be prevented.

This agent could be beneficial in patients with both acute myeloid leukemia and chronic myeloid leukemia, Cortes adds.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x